TheraRadar
Data updated: May 26, 2026

OBREDON (guaifenesin)

Respiratory Approved 2014-11-14
1
Indication
--
Phase 3 Trials
11
Years on Market

Details

Status
Discontinued
First Approved
2014-11-14
Patent Cliff
2035

Pro Metrics

Patent cliff and revenue data

Unlock with Pro
Routes
ORAL
Dosage Forms
SOLUTION

Companies

Active Ingredient: GUAIFENESIN , HYDROCODONE BITARTRATE

OBREDON Approval History

2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
Original
New Indication
New Form
Label Update
6 FDA actions from 2014 to 2025
Dec 2025 SUPPL
Label · Labeling
Dec 2023 SUPPL
Label · Labeling
Jun 2018 SUPPL
Label · Labeling

What OBREDON Treats

1 FDA approvals

Originally approved for its first indication in 2014 .

  • Other (1)
📋

Clinical Trial Registry

2 trials
Trial Sponsor ID Phase Status Title
NCT01202279 Wait and See results posted 2009-MUCD-001 Ph 4 completed Safety and Efficacy Study of Guaifenesin and Pseudoephedrine for Symptomatic Therapy to Treat Acute RTI
NCT01364467 results posted HM13538 Ph 2 completed The Effect of Oral Guaifenesin on Pediatric Chronic Rhinitis: A Pilot Study
🔬

Active Pipeline

Pro

Ongoing clinical trials by development phase

Loading...

Key Completed Trials

Pro

Completed studies with published results, ranked by significance

Loading...
📊

Trial Timeline

Full development history with FDA approval milestones

|
Loading...
Understanding FDA Approval Types
Count Type What it means
- ORIG Original approval - drug first enters market
- SUPPL - Efficacy New indication (new disease/condition approved)
- SUPPL - Labeling Label text changes (warnings, dosing updates)
- SUPPL - Manufacturing Production changes (new facility)
- SUPPL - Chemistry Formulation changes (new dosage strength)

Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.

OBREDON FDA Label Details

View full patent landscape →
3 OB patents · 1 families · 5 international docs across 1 countries

OBREDON Patents & Exclusivity

Latest Patent: Nov 2035

Patents (3 active)

US9549907 Expires Nov 13, 2035
US9808431 Expires Nov 13, 2035
US10105324 Expires Nov 13, 2035
Source: FDA Orange Book

Pro Intelligence Preview

Deep insights for OBREDON

Revenue Insights

  • Quarterly revenue tracking
  • Historical trend analysis

Patent Timeline

  • Cliff: 2035
  • 3 active patents

Trial Analysis

  • Clinical trial tracking
  • Development stage analysis

Competitive Landscape

  • Competitor tracking
  • Same target/indication analysis
Unlock Full Intelligence

Full approval history • All patents • Revenue trends • Competitor analysis

Data Sources

Data sourced from official FDA and NIH databases. Click links to verify on original sources.